JSJanika Schulze

Janika Schulze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Janika Schulze has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Esther van de Vosse

    Laboratory for Pediatric Immunology, Willem-Alexander Children’s Hospital, Leiden University Medical Center 1 Department of Pediatrics Leiden

    2 shared publications
  • Jeannette Werner

    Department of Research and Development, Epimune GmbH, 12489 Berlin, Germany

    2 shared publications
  • Maartje Blom

    Laboratory for Pediatric Immunology, Willem-Alexander Children’s Hospital, Leiden University Medical Center 1 Department of Pediatrics Leiden

    2 shared publications
  • Abigail Lang

    Division of Allergy and Immunology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL

    1 shared publication
  • Akshaya Ramachandran

    Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

    1 shared publication
  • Alice Bertaina

    Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA

    1 shared publication

Latest Publications

  • Identification of unstable regulatory and autoreactive effector T cells that are expanded in patients withFOXP3mutations

    by Šimon Borna, Esmond Lee, Jason Nideffer, Akshaya Ramachandran, Bing Wang, Jeanette Baker, Melissa Mavers, Uma Lakshmanan, Mansi Narula, Amy Kang-Hee Garrett, et al.

    Studies of the monogenic autoimmune disease immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) have elucidated the essential function of the transcription factor FOXP3 and thymic-derived regulatory T cells (Tregs) in controlling peripheral tolerance. However, the presence and the source of autoreactive T cells in IPEX remain undetermined. Here, we investigated how FOXP3 deficiency affects the T cell receptor (TCR) repertoire and Tregstability in vivo and compared T cell abnormalities in patients with IPEX with those in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED). To study Tregsindependently of their phenotype and to analyze T cell autoreactivity, we combined Treg-specific demethylation region analyses, single-cell multiomic profiling, and bulk TCR sequencing. We found that patients with IPEX, unlike patients with APECED, have expanded autoreactive T cells originating from both autoreactive effector T cells (Teffs) and Tregs. In addition, a fraction of the expanded Tregsfrom patients with IPEX lost their phenotypic and functional markers, including CD25 and FOXP3. Functional experiments with CRISPR-Cas9–mediated FOXP3 knockout Tregsand Tregsfrom patients with IPEX indicated that the patients’ Tregsgain a TH2-skewed Teff-like function, which is consistent with immune dysregulation observed in these patients. Analyses ofFOXP3mutation-carrier mothers and a patient with IPEX after hematopoietic stem cell transplantation indicated that Tregsexpressing nonmutatedFOXP3prevent the accumulation of autoreactive Teffsand unstable Tregs. These findings could be directly used for diagnostic and prognostic purposes and for monitoring the effects of immunomodulatory treatments.


  • Open Access

    Epigenetic Immune Cell Counting to Analyze Potential Biomarkers in Preterm Infants: A Proof of Principle in Necrotizing Enterocolitis

    by Michiel H. D. Schoenaker, Mara O. Zuiderwijk, Vincent Bekker, Robbert G. M. Bredius, Jeannette Werner, Janika J. Schulze, Mirjam van der Burg, Maartje Blom

    Epigenetic immune cell counting is a DNA (de)methylation-based technique which can be used to quantify lymphocyte subsets on dried blood spots (DBS). The foregoing techniques allow for a retrospective investigation of immune cell profiles in newborns. In this study, we used this technique for determining lymphocyte subcounts as a potential biomarker for necrotizing enterocolitis (NEC). We investigated whether this technique can be implemented in the field of neonatology, by testing whether regulatory T cell (Treg) levels are pre-existently low in preterms with NEC. Newborn screening (NBS) cards from 32 preterms with NEC and 32 age- and weight-matched preterm controls, and 60 healthy term newborns, were analyzed. Relative and absolute cell counts were determined for CD3+, CD4+, CD8+, Th17, and Treg T cells. For both relative and absolute cell counts of CD3+, CD4+, CD8+, and Th17 T cells, significant differences were found between healthy term controls and both preterm groups, but not between preterm groups. For Tregs, no significant differences were found in either relative or absolute counts between any of the newborn groups. This study demonstrates the principle of epigenetic immune cell counting to analyze lymphocyte subsets in preterm neonates.


  • Open Access

    Second Tier Testing to Reduce the Number of Non-actionable Secondary Findings and False-Positive Referrals in Newborn Screening for Severe Combined Immunodeficiency

    by Maartje Blom, Ingrid Pico-Knijnenburg, Sandra Imholz, Lotte Vissers, Janika Schulze, Jeannette Werner, Robbert Bredius, Mirjam van der Burg

    Purpose: Newborn screening (NBS) for severe combined immunodeficiency (SCID) is based on the detection of T-cell receptor excision circles (TRECs). TRECs are a sensitive biomarker for T-cell lymphopenia, but not specific for SCID. This creates a palette of secondary findings associated with low T-cells that require follow-up and treatment or are non-actionable. The high rate of (non-actionable) secondary findings and false-positive referrals raises questions about the harm-benefit-ratio of SCID screening, as referrals are associated with high emotional impact and anxiety for parents.Methods: An alternative quantitative TREC PCR with different primers was performed on NBS cards of referred newborns (N = 56) and epigenetic immune cell counting was used as for relative quantification of CD3 + T-cells (N = 59). Retrospective data was used to determine the reduction in referrals with a lower TREC cutoff value or an adjusted screening algorithm.Results: When analyzed with a second PCR with different primers, 45% of the referrals (25/56) had TREC levels above cutoff, including four false-positive cases in which two SNPs were identified. With epigenetic qPCR, 41% (24/59) of the referrals were within the range of the relative CD3 + T-cell counts of the healthy controls. Lowering the TREC cutoff value or adjusting the screening algorithm led to lower referral rates but did not prevent all false-positive referrals.Conclusions: Second tier tests and adjustments of cutoff values or screening algorithms all have the potential to reduce the number of non-actionable secondary findings in NBS for SCID, although second tier tests are more effective in preventing false-positive referrals.